Kiadis licens­es pre­vi­ous­ly undis­closed pre-clin­i­cal K-NK-cell pro­grams to Sanofi, with total poten­tial deal val­ue of €875 mil­lion, plus roy­al­ties

  • Combination of Kiadis’ CD38 knock out K-NK cells with Sanofi’s anti-CD38 anti­body Sarclisa® enables opti­mal tumor cell killing, and offers a poten­tial first-in-class treat­ment for patients with mul­ti­ple myelo­ma
  • Kiadis receives €17.5 mil­lion up front pay­ment; poten­tial for up to €857.5 mil­lion in pre­clin­i­cal, clin­i­cal, reg­u­la­to­ry and com­mer­cial mile­stone pay­ments, and up to dou­ble-dig­it roy­al­ties 
  • Kiadis to hold con­fer­ence call with investors and ana­lysts at 16:00 CET today

Amsterdam, The Netherlands, July 8, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal-stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive nat­ur­al killer cell ther­a­pies for patients with life-threat­en­ing dis­eases, today announces the exclu­sive license of Kiadis’ pre­vi­ous­ly undis­closed K-NK004 pro­gram to Sanofi. The agree­ment cov­ers Kiadis’ pro­pri­etary CD38 knock out (CD38KO) K-NK ther­a­peu­tic for com­bi­na­tion with anti-CD38 mon­o­clon­al anti­bod­ies, includ­ing Sarclisa®, Sanofi’s recent­ly approved ther­a­py for patients with mul­ti­ple myelo­ma. Additionally, Sanofi has obtained exclu­sive rights to use Kiadis’ K-NK plat­form for two undis­closed pre-clin­i­cal pro­grams.

As part of the agree­ment, Kiadis will receive a €17.5 mil­lion up front pay­ment and will be enti­tled to receive up to €857.5 mil­lion upon Sanofi’s achieve­ment of pre­clin­i­cal, clin­i­cal, reg­u­la­to­ry and com­mer­cial mile­stones. Kiadis will also receive up to low dou­ble-dig­it roy­al­ties based on com­mer­cial sales of approved prod­ucts result­ing from this agree­ment.  

Natural killer (NK) cells are the human body’s first line of defense against can­cer and infec­tions. Antibodies work syn­er­gis­ti­cal­ly with NK cells to kill tumor cells in a process called anti­body-depen­dent cell-medi­at­ed cyto­tox­i­c­i­ty (ADCC). Treatment of mul­ti­ple myelo­ma with anti-CD38 anti­bod­ies, such as Sarclisa®, deplete the patients’ own NK cells, as nat­ur­al NK cells also express CD38. Kiadis’ CD38KO K-NK cells are NK cells that have been mod­i­fied to pre­vent expres­sion of CD38, and are thus resis­tant to this effect. Therefore, adjunc­tive infu­sion of CD38KO K-NK cells will rein­vig­o­rate the nat­ur­al syn­er­gy between NK cells and anti­bod­ies to kill tumor cells, opti­miz­ing effi­ca­cy.

Arthur Lahr, chief exec­u­tive offi­cer of Kiadis, com­ment­ed, “We are proud to announce this col­lab­o­ra­tion with Sanofi, which marks the start of the pre­vi­ous­ly undis­closed K-NK004 pro­gram and expands the appli­ca­tion of our K-NK plat­form into mul­ti­ple myelo­ma. The agree­ment with Sanofi –  with their world-class exper­tise and approved anti-CD38 mon­o­clon­al anti­body, Sarclisa, in mul­ti­ple myelo­ma and deep under­stand­ing of NK-cell biol­o­gy – is a tes­ta­ment to the ground­break­ing poten­tial of our K-NK nat­ur­al killer cell plat­form to treat life-threat­en­ing dis­eases.”

John Reed, Global Head of Research and Development at Sanofi, com­ment­ed, “The licens­ing of Kiadis’ CD38KO K-NK cells is par­tic­u­lar­ly excit­ing for Sanofi since we will be study­ing this cell-based ther­a­peu­tic with our recent­ly FDA approved treat­ment for patients with dif­fi­cult-to-treat mul­ti­ple myelo­ma, in hopes of bring­ing even more options to these patients with this hema­to­log­ic can­cer. At Sanofi, we are com­mit­ted to pio­neer­ing treat­ments that address unmet health­care chal­lenges. Innovative col­lab­o­ra­tions, such as this part­ner­ship with Kiadis, have the poten­tial to expand the clin­i­cal ben­e­fits of our med­i­cines by com­bin­ing them with syn­er­gis­tic part­nered ther­a­peu­tics to deliv­er improved out­comes for patients.”

About the Sanofi-Kiadis License Agreement
Sanofi has received exclu­sive world­wide rights to research, devel­op and com­mer­cial­ize K-NK004 based on Kiadis’ CD38KO K-NK cells in com­bi­na­tion with CD38-tar­get­ing mol­e­cules for the treat­ment of mul­ti­ple myelo­ma and oth­er CD38 pos­i­tive blood can­cers. Recently, Sanofi received U.S. Food and Drug Administration (FDA) approval for Sarclisa, a mon­o­clon­al anti­body that tar­gets CD38, for the treat­ment of mul­ti­ple myelo­ma.  Additionally, Sanofi has obtained exclu­sive rights to use Kiadis’ K-NK plat­form for two oth­er pre­vi­ous­ly undis­closed pre-clin­i­cal pro­grams. The license does not include rights to K-NK002 and K-NK003 or to any oth­er cur­rent and future Kiadis pro­grams.

Under the terms of this agree­ment, Sanofi will be respon­si­ble for and bear all costs relat­ed to the research and devel­op­ment, man­u­fac­tur­ing, reg­u­la­to­ry and com­mer­cial activ­i­ties relat­ed to the licensed K-NK pro­grams. Kiadis has retained exclu­sive rights to and will sup­ply PM21 par­ti­cles and select uni­ver­sal donors for Sanofi, paid for by Sanofi.

About Multiple Myeloma
Multiple myelo­ma is the sec­ond most com­mon hema­to­log­ic malig­nan­cy,1 affect­ing more than 130,000 patients in the United States; approx­i­mate­ly 32,000 Americans2 are diag­nosed with mul­ti­ple myelo­ma each year. Despite avail­able treat­ments, mul­ti­ple myelo­ma remains an incur­able malig­nan­cy, and is asso­ci­at­ed with sig­nif­i­cant patient bur­den. As patients relapse, they can become refrac­to­ry to ther­a­pies they have received. There is a need for new agents so that patients and physi­cians can have options as the dis­ease pro­gress­es over time.

Leave a Reply

Your email address will not be published. Required fields are marked *